STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £55.86m
- £68.28m
- $49.70m
Brief: Shield Therapeutics Says Loan Facility Extended To Up To $50 Million
Shield Therapeutics - Amends Senior Secured Debt Financing
Brief: Shield Therapeutics Says Accrufer Receives Marketing Authorisation In South Korea
Shield Therapeutics - ACCRUFeR receives Authorisation by Korean Ministry
Shield Therapeutics - Q3 2025 Trading Update
Shield Therapeutics - Grant of Share Options to Chief Executive Officer
Brief: Shield Therapeutics Announces Positive Results In Pediatric Trial
Brief: Shield Therapeutics Announces 1.5 million Pound Placing Supporting Growth Of Accrufer
Shield Therapeutics - £1.5 million placing supporting growth of ACCRUFeR
Brief: Shield Therapeutics Says ACCRUFeR Assigned Priority Review In US By FDA
Brief: Shield Therapeutics PLC Says Guidance Remains On Track To Turn Cash Flow Positive By End Of 2025
Brief: Shield Therapeutics Plc H1 Group Revenues $21.4 Mln
Shield Therapeutics - Interim results for the six months ended 30 Jun 25
Brief: Shield Therapeutics Says On Track To Turn Cash Flow Positive By End 2025
Shield Therapeutics - Q2 2025 Trading Update
Shield Therapeutics - Audited results for the year ended 31 Dec 2024
Brief: Shield Therapeutics Says Signed Licence Agreement In Japan For Accrufer
Shield Therapeutics - Licence Agreement in Japan for ACCRUFeR®
Brief: Vital KSK Holdings Inc - Conclusion Of Exclusive License Agreement Of Shield Therapeutics PLC's Iron Deficiency Treatment By Consolidated Subsidiary